Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets).
Enanta Pharmaceuticals公司（纳斯达克：ENTA）是一家专注于为病毒学和免疫学适应症研发小分子药物的临床阶段生物技术公司，今天宣布，马萨诸塞州地区法院（"法院"）已就辉瑞公司提出的总结判决动议作出裁决，该动议与Enanta的专利侵权诉讼有关，Enanta在该诉讼中寻求因辉瑞公司在制造、使用和销售辉瑞的COVID-19抗病毒药物Paxlovid（nirmatrelvir片；ritonavir片）而侵权U.S. Patent No. 11,358,953（"953专利"）的损害赔偿。
The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.
法院作出了授予辉瑞动议的总结判决决策，认为953专利无效。在其决定中，法院还基于允许无效的总结判决，否决了Enanta关于侵权的部分总结判决动议，认为其无关紧要。Enanta计划向联邦巡回上诉法院上诉该决定。
